246 related articles for article (PubMed ID: 10612518)
1. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Am J Ophthalmol; 1999 Dec; 128(6):763-5. PubMed ID: 10612518
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Am J Ophthalmol; 2000 May; 129(5):678-80. PubMed ID: 10844070
[TBL] [Abstract][Full Text] [Related]
3. Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Yamamoto S; Yamamoto T; Tsukahara I; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Jpn J Ophthalmol; 2002; 46(2):218-21. PubMed ID: 12062231
[TBL] [Abstract][Full Text] [Related]
4. Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Takeuchi S; Ohtsuka K; Matsuda A; Yamamoto T; Yamamoto S; Hiraiwa N; Kusakabe M
Ophthalmologica; 2003; 217(6):422-5. PubMed ID: 14573976
[TBL] [Abstract][Full Text] [Related]
5. Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Wang ZY; Shen LJ; Zhao KK; Song ZM; Qu J
Ophthalmic Res; 2009; 42(3):138-40. PubMed ID: 19602911
[TBL] [Abstract][Full Text] [Related]
6. Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Ogata N; Nishikawa M; Nishimura T; Mitsuma Y; Matsumura M
Am J Ophthalmol; 2002 Jun; 133(6):851-2. PubMed ID: 12036691
[TBL] [Abstract][Full Text] [Related]
7. Soluble TNF receptors in vitreoretinal proliferative disease.
Limb GA; Hollifield RD; Webster L; Charteris DG; Chignell AH
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
[TBL] [Abstract][Full Text] [Related]
8. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy.
Mitamura Y; Takeuchi S; Matsuda A; Tagawa Y; Mizue Y; Nishihira J
Br J Ophthalmol; 2000 Jun; 84(6):636-9. PubMed ID: 10837392
[TBL] [Abstract][Full Text] [Related]
9. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders.
Abu el-Asrar AM; Van Damme J; Put W; Veckeneer M; Dralands L; Billiau A; Missotten L
Am J Ophthalmol; 1997 May; 123(5):599-606. PubMed ID: 9152065
[TBL] [Abstract][Full Text] [Related]
10. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
[TBL] [Abstract][Full Text] [Related]
11. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
Dieudonné SC; La Heij EC; Diederen RM; Kessels AG; Liem AT; Kijlstra A; Hendrikse F
Ophthalmic Res; 2007; 39(3):148-54. PubMed ID: 17534114
[TBL] [Abstract][Full Text] [Related]
12. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment.
Ogata N; Tombran-Tink J; Nishikawa M; Nishimura T; Mitsuma Y; Sakamoto T; Matsumura M
Am J Ophthalmol; 2001 Sep; 132(3):378-82. PubMed ID: 11530051
[TBL] [Abstract][Full Text] [Related]
13. Levels of some cytokines in subretinal fluid in proliferative vitreoretinopathy and rhegmatogenous retinal detachment.
Kenarova B; Voinov L; Apostolov C; Vladimirova R; Misheva A
Eur J Ophthalmol; 1997; 7(1):64-7. PubMed ID: 9101198
[TBL] [Abstract][Full Text] [Related]
14. Distinct Serum and Vitreous Inflammation-Related Factor Profiles in Patients with Proliferative Vitreoretinopathy.
Ni Y; Qin Y; Huang Z; Liu F; Zhang S; Zhang Z
Adv Ther; 2020 May; 37(5):2550-2559. PubMed ID: 32274748
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the molecular biologic milieu of the vitreous in proliferative vitreoretinopathy.
Wladis EJ; Falk NS; Iglesias BV; Beer PM; Gosselin EJ
Retina; 2013 Apr; 33(4):807-11. PubMed ID: 23222459
[TBL] [Abstract][Full Text] [Related]
17. Placenta growth factor and vascular endothelial growth factor in the vitreous of patients with proliferative vitreoretinopathy.
Mitamura Y; Tashimo A; Ohtsuka K; Mizue Y; Nishihira J
Clin Exp Ophthalmol; 2005 Apr; 33(2):226-7. PubMed ID: 15807839
[No Abstract] [Full Text] [Related]
18. Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy.
Barile GR; Chang SS; Park LS; Reppucci VS; Schiff WM; Schmidt AM
Curr Eye Res; 1999 Sep; 19(3):219-27. PubMed ID: 10487959
[TBL] [Abstract][Full Text] [Related]
19. The role of thrombin in proliferative vitreoretinopathy.
Bastiaans J; van Meurs JC; Mulder VC; Nagtzaam NM; Smits-te Nijenhuis M; Dufour-van den Goorbergh DC; van Hagen PM; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4659-66. PubMed ID: 25015355
[TBL] [Abstract][Full Text] [Related]
20. Correlation of transforming growth factor β-1 vitreous levels with clinical severity of proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment.
Palomares-Ordóñez JL; Sánchez-Ramos JA; Ramírez-Estudillo JA; Robles-Contreras A
Arch Soc Esp Oftalmol (Engl Ed); 2019 Jan; 94(1):12-17. PubMed ID: 30309666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
